Cigna Group (NYSE:CI) Sets New 52-Week High Following Earnings Beat

Cigna Group (NYSE:CI) shares reached a new 52-week high during mid-day trading on Thursday following a stronger than expected earnings report. The stock traded as high as $318.05 and last traded at $312.8470, with a volume of 257,944 shares traded. The stock had previously closed at $305.41.

The health services provider reported $7.98 earnings per share for the quarter, beating the consensus estimate of $7.52 by $0.46. Cigna Group had a return on equity of 19.75% and a net margin of 2.27%. During the same period last year, the business earned $7.83 EPS. The firm’s revenue was up 5.6% on a year-over-year basis.

Cigna Group Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Thursday, December 3rd will be paid a $1.56 dividend. The ex-dividend date of this dividend is Thursday, December 3rd. This represents a $6.24 dividend on an annualized basis and a dividend yield of 2.0%. Cigna Group’s dividend payout ratio is 25.82%.

Key Cigna Group News

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Third-quarter adjusted earnings were $7.98 per share, above analyst estimates, while revenue rose 6% to $73.7 billion. Cigna Q3 results and outlook
• Positive Sentiment: Cigna raised its 2026 adjusted income-from-operations outlook to at least $30.60 per share, reinforcing confidence in its earnings trajectory. Cigna raises 2026 outlook
• Positive Sentiment: At Investor Day, the company outlined a long-term target of 10%–14% adjusted EPS growth and about $50 billion in cumulative operating cash flow through 2030, alongside a $3 billion modernization and productivity initiative. Cigna Q3 results and outlook
• Negative Sentiment: GAAP net income fell to $1.4 billion from $1.87 billion a year earlier, and GAAP earnings per share declined to $5.47 from $6.98. One estimate cited in the coverage also put revenue below expectations, tempering the upbeat adjusted results. Cigna lifts outlook as revenue climbs

Wall Street Analyst Weigh In

Several brokerages have commented on CI. Jefferies Financial Group downgraded shares of Cigna Group from a “buy” rating to a “hold” rating and lowered their target price for the company from $336.00 to $307.00 in a research note on Tuesday, August 4th. Guggenheim lifted their price target on shares of Cigna Group from $338.00 to $361.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Evercore initiated coverage on shares of Cigna Group in a research report on Wednesday, September 9th. They set an “in-line” rating and a $290.00 price target on the stock. Royal Bank Of Canada reissued an “outperform” rating and issued a $337.00 price target on shares of Cigna Group in a report on Thursday, October 1st. Finally, Wall Street Zen cut shares of Cigna Group from a “buy” rating to a “hold” rating in a research report on Saturday, October 31st. Fourteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, Cigna Group has a consensus rating of “Moderate Buy” and an average price target of $336.40.

Insider Activity at Cigna Group

In other Cigna Group news, insider Nicole Jones sold 2,677 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $279.61, for a total transaction of $748,515.97. Following the sale, the insider directly owned 25,880 shares in the company, valued at approximately $7,236,306.80. This trade represents a 9.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Everett Neville sold 617 shares of Cigna Group stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $284.05, for a total transaction of $175,258.85. Following the completion of the transaction, the insider directly owned 5,053 shares in the company, valued at approximately $1,435,304.65. The trade was a 10.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Cigna Group

Institutional investors have recently added to or reduced their stakes in the stock. GQG Partners LLC bought a new position in Cigna Group during the 2nd quarter valued at $1,628,918,000. Bank of America Corp DE bought a new stake in shares of Cigna Group in the 2nd quarter worth $827,692,000. Legal & General Group Plc purchased a new stake in shares of Cigna Group in the second quarter valued at about $542,779,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Cigna Group in the second quarter valued at about $241,312,000. Finally, BlackRock Inc. lifted its position in shares of Cigna Group by 3.7% during the second quarter. BlackRock Inc. now owns 23,438,250 shares of the health services provider’s stock valued at $6,461,457,000 after purchasing an additional 840,098 shares in the last quarter. 86.99% of the stock is owned by institutional investors.

Cigna Group Price Performance

The company has a quick ratio of 0.76, a current ratio of 0.76 and a debt-to-equity ratio of 0.68. The business’s 50-day moving average is $285.07 and its two-hundred day moving average is $281.91. The company has a market capitalization of $82.93 billion, a P/E ratio of 13.00, a price-to-earnings-growth ratio of 1.00 and a beta of 0.25.

Cigna Group Company Profile

The Cigna Group (NYSE: CI) is a global health services company that provides insurance coverage, health care benefits and related services. Its operations are primarily organized through Cigna Healthcare, which offers medical, pharmacy, dental, behavioral health and other benefit programs to employers, government organizations and individuals, primarily in the United States.

The company also operates Evernorth Health Services, a health services platform that includes pharmacy benefit management, specialty pharmacy, care management and health-care delivery capabilities.